Clinical Trials Logo

Multiple Primary Lung Cancers clinical trials

View clinical trials related to Multiple Primary Lung Cancers.

Filter by:
  • None
  • Page 1

NCT ID: NCT04982900 Recruiting - Clinical trials for Multiple Primary Lung Cancers

Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

TERMGGO
Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

This study is a multi-center, prospective, double-blind randomized controlled clinical trial. The purpose is to evaluate the efficacy and safety of EGFR-TKI on residual GGOs after surgery in patients with multiple primary lung cancers with ground glass nodules. This study is expected to prove that compared with placebo in the control group, EGFR-TKI can significantly reduce the residual GGOs lesions in patients with EGFR-positive multiple primary lung cancers with ground-glass opacity, and bring a higher objective response rate (ORR), thus provides new insights for treatment of these patients.

NCT ID: NCT04326751 Not yet recruiting - Lung Cancer Clinical Trials

Evolution of Multiple Primary Lung Cancer (Evolution)

Start date: January 1, 2021
Phase:
Study type: Observational

To investigate the evolutionary genomic landscape, explore the genetic tumor heterogeneity and microenvironment of multiple primary lung cancer (MPLC) by using tissue genetic analysis and circulating tumor DNA detection, in order to provide robust evidence for the diagnosis, treatment, and surveillance of MPLC.

NCT ID: NCT04026841 Recruiting - Clinical trials for Multiple Primary Lung Cancers

The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

Start date: July 30, 2019
Phase: Phase 2
Study type: Interventional

A single-center,prospective interventional study to explore the efficacy of PD-1 antibody Sintilimab on early-stage multiple primary lung cancer patients with ground-glass nodules in CT scan.